Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 8/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | HTR3A | P46098 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28749742 | 0.77 | HTR4 (0.65) | HTR4CYP3A4GLAMEN1ALDH1A1 | |
| SCHEMBL7202743 | 0.73 | HTR4 (0.66) | HTR4CYP3A4GLAMEN1ALDH1A1 | |
| SCHEMBL8803576 | 0.73 | HTR4 (0.54) | HTR4CYP3A4GLAMEN1ALDH1A1 | |
| SCHEMBL15652199 | 0.73 | MEN1 (0.66) | HTR4CYP3A4GLAMEN1ALDH1A1 | |
| SCHEMBL2579561 | 0.73 | HTR4 (1.00) | HTR4CYP3A4GLAMEN1ALDH1A1 | |
| SCHEMBL29386039 | 0.73 | HTR4 (1.00) | HTR4CYP3A4GLAMEN1ALDH1A1 | |
| SCHEMBL384749 | 0.72 | GAA (1.00) | HTR4CYP3A4GLAALDH1A1CYP2D6 | |
| Hydrochloric Acid SCHEMBL22532550 | 0.72 | HTR4 (0.98) | HTR4CYP3A4GLAMEN1ALDH1A1 | |
| SCHEMBL11538644 | 0.72 | HTR4 (0.66) | HTR4CYP3A4GLAHTR3AGAA | |
| SCHEMBL29767008 | 0.71 | HTR4 (1.00) | HTR4CYP3A4GLAMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1000029-B1 | (+)-NORCISAPRIDE USEFUL FOR 5-HT3 AND 5-HT4 MEDIATED DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2003-10-01 | — | — | EP | disclosed |